Effect of tolterodine on gastrointestinal transit and bowel habits in healthy subjects

Neurogastroenterology and Motility

Volumn 20, Issue 6, 2008, Pages 643-648

  Bharucha, A E ^a   Seide, B ^a   Guan, Z ^c   Andrews, C N ^a   Zinsmeister, A R ^b  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

^c PFIZER INC   (United States)

Author keywords

Antagonist; Colonic; Gastrointestinal; Muscarinic; Tolterodine; Transit

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; TOLTERODINE;

ADULT; ARTICLE; CONTROLLED STUDY; DEFECATION HABIT; DRUG ABSORPTION; DRUG EFFECT; FEMALE; GASTROINTESTINAL TRANSIT; GEOMETRY; HUMAN; HUMAN EXPERIMENT; MALE; PRIORITY JOURNAL; SCINTIGRAPHY; SEX DIFFERENCE; STOMACH EMPTYING; SUSTAINED RELEASE FORMULATION;

ADULT; BENZHYDRYL COMPOUNDS; CONSTIPATION; CRESOLS; DEFECATION; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRANSIT; HUMANS; MALE; MIDDLE AGED; PHENYLPROPANOLAMINE; URINARY BLADDER, OVERACTIVE;

EID: 43549088527     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2008.01089.x     Document Type: Article

References (29)

1. Abrams P, Andersson KE, Buccafusco JJ et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006 148 : 565 78.
2. Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology 2006 67 : 275 80.
3. Chapple C, Steers W, Norton P et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005 95 : 993 1001.
4. Millard RJ, Halaska M. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis. Curr Med Res Opin 2006 22 : 41 8.
5. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A, Tolterodine Study G. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001 57 : 414 21.
6. Ashraf W, Park F, Lof J, Quigley EM. An examination of the reliability of reported stool frequency in the diagnosis of idiopathic constipation. Am J Gastroenterol 1996 91 : 26 32.
7. Houghton LA, Rogers J, Whorwell PJ, Campbell FC, Williams NS, Goka J. Zamifenacin (UK-76, 654) a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1997 11 : 561 8.
8. Johnson J. Constipation. In : Talley NJ, Locke GR, Saito Y eds. GI Epidemiology. Malden, MA : Blackwell Publishing, 2007 : 184 90.
9. Bharucha AE, Locke GR, McKeon K et al. Differences between painless versus painful constipation. Am J Gastroenterol 2006 101 : 604 12.
10. Bharucha AE, Locke GR, Seide B, Zinsmeister AR. A new questionnaire for constipation and fecal incontinence. Aliment Pharmacol Ther 2004 20 : 355 64.
11. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983 67 : 361 70.
12. Murray L, O'Hare A (eds) Tolterodine tartarate (Detrol). In : Physicians' Diesk Reference, 61, 61st edn. Montvale : Thompson PDR. 2007 : 2631 4.
13. Cremonini F, Mullan BP, Camilleri M, Burton DD, Rank MR. Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment Pharmacol Ther 2002 16 : 1781 90.
14. Viramontes BE, Camilleri M, McKinzie S, Pardi DS, Burton D, Thomforde GM. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001 96 : 2671 6.
15. Gonenne J, Camilleri M, Ferber I et al. Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol 2005 3 : 784 91.
16. Borody TJ, Quigley EM, Phillips SF et al. Effects of morphine and atropine on motility and transit in the human ileum. Gastroenterology 1985 89 : 562 70.
17. Parkman HP, Trate DM, Knight LC, Brown KL, Maurer AH, Fisher RS. Cholinergic effects on human gastric motility. Gut 1999 45 : 346 54.
18. Chiba T, Bharucha AE, Thomforde GM, Kost LJ, Phillips SF. Model of rapid gastrointestinal transit in dogs: effects of muscarinic antagonists and a nitric oxide synthase inhibitor. Neurogastroenterol Motil 2002 14 : 535 41.
19. Eglen RM, Choppin A, Watson N. Therapeutic opportunities from muscarinic receptor research. Trends Pharmacol Sci 2001 22 : 409 14.
20. Harrington AM, Hutson JM, Southwell BR. Localisation of muscarinic receptor M1-M3 immunoreactivity in human colon. Neurogastroenterol Motil 2006 18 : 777.
21. North RA, Slack BE, Surprenant A. Muscarinic M1 and M2 receptors mediate depolarization and presynaptic inhibition in guinea-pig enteric nervous system. J Physiol 1985 368 : 435 52.
22. Schiavone A, Sagrada A, Pagani F, Giachetti A. Role of muscarinic receptor subtypes in the regulation of migrating myoelectric complex in the dog. Gastroenterology 1989 96 : 116 21.
23. Carmine AA, Brogden RN. Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases. Drugs 1985 30 : 85 126.
24. Alabaster VA. Discovery & development of selective M3 antagonists for clinical use. Life Sci 1997 60 : 1053 60.
25. Heaton KW, O'Donnell LJ. An office guide to whole-gut transit time. Patients' recollection of their stool form. J Clin Gastroenterol 1994 19 : 28 30.
26. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997 32 : 920 4.
27. Degen LP, Phillips SF. How well does stool form reflect colonic transit? Gut 1996 39 : 109 13.
28. Sadik R, Abrahamsson H, Ung KA, Stotzer PO. Accelerated regional bowel transit and overweight shown in idiopathic bile acid malabsorption. Am J Gastroenterol 2004 99 : 711 8.
29. Delgado-Aros S, Locke GR 3rd., Camilleri M et al. Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol 2004 99 : 1801 6.